Related Experiment Video
Updated: Jun 24, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
The pharmacodynamics of enoxaparin in percutaneous coronary intervention with precise rapid enoxaparin loading
Jack L Martin1, Edward T A Fry, Todd Martin
1Main Line Health, Sharpe-Strumia Research Foundation, Bryn Mawr Hospital, Bryn Mawr, PA 19010, USA. MartinJ@mlhs.org
Objective:
We evaluated the early pharmacodynamic profile of the combined 30 mg intravenous and 1 mg/kg subcutaneous enoxaparin loading utilized in the TIMI 11B and ExTRACT TIMI 25 trials.
Background:
It has not been reported whether anti-Xa levels appropriate for percutaneous coronary intervention (PCI) can be reliably achieved within 2 h utilizing this regimen.
Methods:
Twenty-six patients with acute coronary syndrome (ACS) treated with this regimen had anti-Xa levels measured at 5 min, 2, 4, 6 and 8 h.
Results:
Seventy-six percent of patients had anti-Xa levels above 0.5 IU/ml at 5 min. Dose-response curves showed all patients to have anti-Xa levels above 0.5 IU/ml within 1 h. Anti-Xa remained in the targeted range for PCI (0.5 to 1.8 IU/ml) at 2, 4, 6 and 8 h in all patients.
Conclusion:
This regimen is well suited for ACS treatment with an invasive strategy, including the rapid transition to early and rescue PCI.
Related Concept Videos
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Acute Coronary Syndrome III: Diagnostic Studies
Cardiac Catheterization I: Pre-Procedure Overview
Acute Coronary Syndrome IV: Interprofessional Care
Pharmacokinetic–Pharmacodynamic Relationship: Problems
